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Background: The widespread adoption of high-throughput sequencing technologies by genetic diagnostic
laboratories has enabled significant expansion of their testing portfolios. Rare autosomal recessive conditions have
been a particular focus of many new services. Here we report a cohort of 26 patients referred for genetic analysis
of Joubert (JBTS) and Meckel-Gruber (MKS) syndromes, two clinically and genetically heterogeneous
neurodevelopmental conditions that define a phenotypic spectrum, with MKS at the severe end.
Methods: Exome sequencing was performed for all cases, using Agilent SureSelect v5 reagents and Illumina
paired-end sequencing. For two cases medium-coverage (9×) whole genome sequencing was subsequently
undertaken.
Results: Using a standard analysis pipeline for the detection of single nucleotide and small insertion or deletion
variants, molecular diagnoses were confirmed in 12 cases (4 %). Seeking to determine whether our cohort
harboured pathogenic copy number variants (CNV), in JBTS- or MKS-associated genes, targeted comparative
read-depth analysis was performed using FishingCNV. These analyses identified a putative intragenic AHI1 deletion
that included three exons spanning at least 3.4 kb and an intergenic MPP4 to TMEM237 deletion that included
exons spanning at least 21.5 kb. Whole genome sequencing enabled confirmation of the deletion-containing alleles
and precise characterisation of the mutation breakpoints at nucleotide resolution. These data were validated
following development of PCR-based assays that could be subsequently used for “cascade” screening and/or
prenatal diagnosis.
Conclusions: Our investigations expand the AHI1 and TMEM237 mutation spectrum and highlight the importance
of performing CNV screening of disease-associated genes. We demonstrate a robust increasingly cost-effective
CNV detection workflow that is applicable to all MKS/JBTS referrals.
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In recent years the widespread adoption of next-generation
sequencing technologies has led to step-wise improve-
ments in the provision of diagnostic testing services. This
was initially a result of an improvement in testing efficiency
focusing on single-gene assays, but has more recently been
due to ‘panel testing’, whereby numerous genes are ana-
lysed concurrently in a single assay. A natural progression
of this approach is to perform whole exome sequencing
and analyse a “virtual” gene panel, comprising a subset of
the sequenced loci. Extremely heterogeneous disorders,
overlapping a spectrum of clinical phenotypes, are ideally
suited to analysis by these new approaches and have en-
abled diagnostic laboratories to significantly expand their
test portfolios.
We have used virtual exome panels for diagnosis of sev-
eral heterogeneous autosomal recessive disorders, includ-
ing primary ciliary dyskinesia (PCD; OMIM: 244400), one
of a number of disorders prevalent in our local commu-
nity [1]. Patients present with recurrent respiratory infec-
tions, male infertility and heterotaxy in approximately
50 % of cases. Although cilia are ubiquitous, PCD is
caused by defects specifically in the motile cilia that are
required for embryonic gastrulation, for clearance of re-
spiratory tract mucosa, and to propel spermatozoa [2].
Standing in contrast are a number of ciliopathies caused
by mutations in immotile cilia. These disorders present
pleiotropic clinical abnormalities, often of the central
nervous system, eye and skeleton, as well as cystic kidney
disease. They are relatively common Mendelian conditions
with an estimated combined prevalence of 1 in 2000 [3].
Two ciliopathies with overlapping features and consid-
erable underlying genetic heterogeneity are Joubert (JBTS;
OMIM: 213300) and Meckel-Gruber (MKS; OMIM:
249000) syndromes, which are currently associated with
31 and 13 genes respectively, ten of which are docu-
mented to cause both conditions. JBTS is characterised by
neurodevelopmental abnormalities in conjunction with
a pathognomonic neuroradiological finding (the molar
tooth sign). The latter results from cerebellar vermis
hypoplasia or aplasia, elongated superior cerebellar pe-
duncles and a deep interpeduncular fossa. Patients often
present with a lack of balance and coordination and a
wide spectrum of associated features occur, including
postaxial polydactyly, retinal degeneration, cleft lip, sei-
zures, as well as renal and hepatic disease [4]. While some
children die in infancy most survive, with variable devel-
opmental outcomes. In contrast, MKS is typically a peri-
natally lethal syndrome characterised by posterior fossa
abnormalities (most frequently occipital encephalocele),
bilateral enlarged cystic kidneys, postaxial polydactyly and
hepatic ductal plate malformation.
Given the overlapping genetic etiologies of these condi-
tions, a pragmatic solution to robust molecular diagnosticinvestigation is to undertake concurrent mutation analysis
of all JBTS/MKS reported genes. Although this strategy is
broadly applicable to heterogeneous conditions, individual
populations exist in which a more targeted approach is
likely to be more cost-effective. One such example is the
high prevalence of MKS1 and CC2D2A mutations present
in the Finnish population, as a result of founder effects
caused by their genetic isolation [5, 6]. Similarly, numer-
ous JBTS patients of French-Canadian origin have been
identified with mutations in TMEM237 or C5orf42 [7].
Nonetheless, broader routine genetic analysis using NGS
gene panels facilitates the establishment of genotype-
phenotype correlations in these disorders. The ultimate
aim of such analyses is to enable improved variant classifi-
cation and prognostic assessment. The most compelling re-
ported association is between COACH syndrome (OMIM:
216360), a JBTS-related disorder for which patients have
JBTS with liver involvement or coloboma, and mutations
in TMEM67 [8]. In terms of allelic spectrum, missense
mutations in CC2D2A have been reported to cause JBTS
whereas null alleles cause MKS [9]. Such studies are reli-
ant on thorough phenotype data. While this information
is often not available to the diagnostic laboratories under-
taking the mutation analysis, centralised large-scale rese-
quencing projects are increasingly mandating use of
structured phenotype ontologies which will alleviate this
problem.
Here we present our experience of using a standard
diagnostic pipeline to perform point mutation and
small insertion/deletion variant detection in a series
of patients referred with either JBTS or MKS. We
undertook whole exome sequencing and analysed a
virtual panel of JBTS- and MKS-associated genes. We
subsequently used these data to undertake exome-
based CNV analysis to identify exon deletion and/or
duplication variants that are typically smaller than
those that can be resolved using standard array CGH
platforms. Positive CNV analysis results were vali-
dated using whole genome sequencing (WGS) and split
read mapping to identify breakpoint sequences at nucleo-
tide resolution.
Methods
DNA was isolated from blood or fetal tissue of 26 af-
fected individuals using standard salting out or phenol/
chloroform extraction protocols. (The developmental
age of the individuals ranged from prenatal to 4 years.)
All patients were referred to the Yorkshire Regional
Genetics Laboratory, Leeds, for diagnostic testing with a
clinical diagnosis of either JBTS (9 patients) or MKS (17
patients). The Leeds East Research Ethics Committee
granted ethical approval (07/H1306/113) and written in-
formed consent was obtained from the parents or next
of kin of all individuals.
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Diagnostic mutation analysis of JBTS- and MKS-associated
genes (Additional file 1: Table S1) was performed using
exome-enriched sequence data. Genomic DNA (3 μg) was
first sheared into 200–300 bp fragments using a Covaris S2
(Covaris, Inc., Woburn, MA, USA). SureSelect XT reagents
(Agilent Technologies, Wokingham, UK) were used to per-
form end-repair, A-addition and adaptor ligation reactions
to generate Illumina-compatible sequencing libraries. Hy-
bridisation capture enrichment of whole genome libraries
was performed using the SureSelect v5 all-exon probe set,
following manufacturer’s recommendations throughout.
Equimolar aliquots of 5 post-enrichment libraries were
pooled before sequencing using version 3 TruSeq chemis-
try on a HiSeq 2500 (Illumina Inc., San Diego, CA, USA).
Paired-end 100-bp sequence reads were “demultiplexed”
using CASAVA v.1.8.2 and the resulting per-sample
FASTQ.gz files were aligned to an indexed reference gen-
ome (hg19) using bwa v.0.6.2 (http://bio-bwa.sourcefor
ge.net) [10]. Duplicate reads were removed using Picard
v.1.85 (http://picard.sourceforge.net) before indel realign-
ment, base quality score recalibration and variant discovery
were performed using the Genome Analysis Toolkit
(GATK) v.2.3-4Lite [11]. Identified variants were saved in
variant call format (VCF) and then annotated with pos-
itional, frequency and functional in silico predictions using
Alamut Batch standalone v.1.4.0, (database v.2015.04.30)
(Interactive Biosoftware, Rouen, France). These pro-
grams included SIFT (http://sift.jcvi.org), and AlignGVGD
(http://agvgd.iarc.fr/agvgd_input.php). AgileExomeFilter
[1] was used to interrogate these data and determine the
pathogenicity status of each variant in accordance with
the Association for Clinical Genetic Science best practice
guidelines [12]. Manual inspection of aligned sequence
reads was performed using the Integrative Genome
Viewer v.2.3.52 [13]. To determine assay performance, the
number of sequence reads mapping to targeted genomic
intervals was calculated for each patient using the GATK
DepthOfCoverage walker. Exon-based copy number
analysis was performed on coordinate-sorted duplicate-
cleaned BAM files using FishingCNV v.2.1 [14]. The refer-
ence control pool for the copy number analyses comprised
65 patients referred for disorders other than JBTS or
MKS. Inter-batch variability was reduced using the Fish-
ingCNV principal component option (−pca) for all sam-
ples analysed.
Medium coverage whole genome sequencing
To verify variants identified by FishingCNV, and to
validate their intragenic breakpoints, whole genome li-
braries were generated and sequenced. Approximately
1 μg of DNA was sheared into 200–300-bp fragments
using a Covaris S2, and an Illumina-compatible sequen-
cing library generated using NEBNext® Ultra™ reagents(New England Biolabs, Ipswich, MA, USA). The insert
size was ~250 bp and the final enrichment PCR com-
prised six rounds of thermocycling. Each patient library
was sequenced on a single lane of a HiSeq 2500 rapid
mode flow cell, generating 175-bp sequence reads. Raw
data was converted to FASTQ.gz format using CASAVA
v.1.8.2. Adaptor sequences were trimmed from the ends
of the sequence reads using Cutadapt v.1.1 (https://cuta-
dapt.readthedocs.org) [15] before alignment to the hu-
man genome (hg19) using bwa v.0.6.2. Reads that
remained unmapped to the reference genome were
extracted from the duplicate-cleaned coordinate-sorted
BAM files and converted to FASTQ format using bam2-
fastq v.1.1.0 (http://gsl.hudsonalpha.org/information/soft-
ware/bam2fastq). For each patient, split read alignments
were performed using SplazerS v.1.1 against a FASTA
reference sequence that included the FishingCNV-
defined CNV (http://www.seqan.de/projects/splazers/) [16].
Breakpoint-spanning reads were identified following inter-
pretation of the alignment CIGAR string. BLAT was then
used to determine the genomic coordinates of the 5′ and
3′ fragments (http://genome.ucsc.edu/cgi-bin/hgBlat) [17].
PCR confirmation assays and Sanger sequencing
PCR amplicons were designed to span SplazerS-identified
breakpoints. The primers used to amplify the TMEM237/
MPP4 deletion-containing allele were dTGTAAAACGA
CGGCCAGTACAGGTGGAAGAGCTCGTG (common
forward) and dCAGGAAACAGCTATGACCTCTTCAG
TATCACCCCAGACA (reverse deletion), which gener-
ated a 482-bp product. A second reverse primer (dCAGG
AAACAGCTATGACCCCACCACTTTCAGAGGCCAA)
was used with the common forward primer to generate a
399-bp PCR product specific for the normal allele. The
primers used to amplify the AHI1 deletion-containing al-
lele were dTGTAAAACGACGGCCAGTTCAAAAGCCC
TCTCCTGTAGT (deletion forward) and dCAGGAAAC
AGCTATGACCATCTTGGGTTTCTGCACACA (com-
mon reverse), which generated a 582-bp product. A sec-
ond forward primer (dTGTAAAACGACGGCCAGTAT
GTGTCAGGGATCCTCAGG) together with the com-
mon reverse primer yielded a smaller 356-bp PCR product
specific for the normal allele. Each PCR consisted of
0.5 μl of genomic DNA (250 ng/μl), 11 μl of Mega-
Mix (Microzone Ltd., Haywards Heath, UK), 1 μl of
10 pmol/μl forward primer and 1 μl of 10 pmol/μl re-
verse primer. Each primer contained a universal tag
(underlined) allowing Sanger sequencing according to
our standard laboratory workflow. Thermocycling condi-
tions consisted of 5 min at 94 °C then 30 cycles of 94 °C
for 30 s, 60 °C for 1 min, and 72 °C for 45 s before a final
extension step at 72 °C for 5 min. To facilitate rapid
and robust cascade screening, optimal AHI1 primer
concentrations were determined to allow a three-primer
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tris-borate-EDTA agarose gel.
Sanger sequencing was used to confirm all variants in-
cluded on clinical reports; manufacturer’s protocols were
followed throughout (Applied Biosystems, Paisley, UK).
Primer details and thermocycling conditions are avail-
able on request. Sequence chromatograms were analysed
using Mutation Surveyor v.3.2 (SoftGenetics LLC, State
College, PA, USA).
Results
We have previously implemented a “targeted exome” diag-
nostic test for primary ciliary dyskinesia [1]. By using the
same lab-bench workflow with a modified informatics
pipeline, this test has been expanded to include two add-
itional rare recessive conditions, JBTS and MKS. The 34
currently known JBTS and MKS disease-associated genes
were included in our analyses; these comprise more than
700 exons and 33 kb of coding sequence (Additional file 1:
Table S1). Average read count per patient was 92.4 million
reads of which ~9.8 % were identified as PCR duplicates
(Additional file 1: Table S2). This is slightly higher than
our typical duplicate rate and may reflect the limited
quantity and quality of the available DNA samples. The
percentage of reads mapping to exome-located nucleo-
tides (~59 %) is consistent with previous reports [18] and
corresponds to ~48 million reads per exome. Approxi-
mately 86 % of target nucleotides per sample (coding
bases plus 20-bp of flanking intron) were sequenced by at
least 30 reads (Additional file 1: Table S3).
Variant interrogation was restricted to the 34 known
disease-associated genes. This reduced the average totalTable 1 Pathogenic variants identified following routine diagnostic
Sample number Gene Transcript Allele 1
1 AHI1 NM_001134830.1 c.1983del (p.T
2 AHI1 NM_001134830.1 c.2495del (p.L
3 CC2D2A NM_001080522.2 c.2803C > T (p
4 CC2D2A NM_001080522.2 c.2875del (p.G
5 CEP290 NM_025114.3 c.1975A > T (p
6 MKS1 NM_017777.3 c.262-2A > G (
7 TCTN2 NM_024809.4 c.1506-2A > G
8 TCTN2 NM_024809.4 c.1506-2A > G
9 TCTN2 NM_024809.4 c.1506-2A > G
10 TCTN2 NM_024809.4 c.1506-2A > G
11 TMEM67 NM_153704.5 c.415_416del
12 TMEM67 NM_153704.5 c.514C > T (p.A
13 TMEM67 NM_153704.5 c.579_580del
14 TMEM67 NM_153704.5 c.1319G > A (p
15 TMEM67 NM_153704.5 c.1960 + 1G >
16 TMEM237 NM_001044385.2 c.709del (p.Alavariant count from 33,766 to 70 per patient (Additional
file 1: Table S4). By excluding common variants (minor
allele frequency 0.05) the burden of manual interpret-
ation was reduced to approximately eight variants per
patient. The disease-associated pathogenicity status of
each of these was classified according to the Association
for Clinical Genetic Science best practice guidelines [12].
In this way a confirmatory molecular diagnosis was
achieved in 12 out of 26 cases (46 %) (Table 1). The muta-
tion spectrum was largest for TMEM67, which harboured
seven different pathogenic mutations in our cohort.
The most frequently identified pathogenic mutation
was TCTN2 c.1506-2A >G (p.?) [GenBank:NM_024809.4],
which was detected seven times.
In patients, the diagnosis of JBTS or MKS could not
be confirmed, either (a) because the identified variant(s)
was classified as probably benign, or a variant of uncer-
tain significance or (b) because the patient was a carrier
of only a single bona fide pathogenic mutation (four in-
dividuals). We performed exome-based copy number
analysis of the JBTS- and MKS-associated disease genes
for all patients in the cohort (data not shown). Heterozy-
gous multi-exon deletions were identified in two separate
patients. Both of these subjects were also carriers of
pathogenic single-nucleotide deletions in the correspond-
ing gene. For patient 1 the deletion reported by Fish-
ingCNV spanned at least 3.4 kb and included AHI1 exons
14–16 [GenBank:NM_001134830.1] (Additional file 2: Fig-
ure S1). For patient 16, the detected deletion extended
from TMEM237 exon 1a [GenBank:NM_152388.3] to
MPP4 exon 14 [GenBank:NM_003066.2], spanning at least
21.5 kb and 11 exons. For both variants, the maximaltesting
Allele 2 Reference(s)
rp662Glyfs*24) No mutation detected
eu832*) c.2495del (p.Leu832*) [24, 25]
.Arg935*) c.3774dup (p.Glu1259*)
lu959Asnfs*3) c.2875del (p.Glu959Asnfs*3)
.Lys659*) c.5668G > T (p.Gly1890*) [26–28]
p.?) No mutation detected
(p.?) No mutation detected [29]
(p.?) c.1506-2A > G (p.?) [29]
(p.?) c.1506-2A > G (p.?) [29]
(p.?) c.1506-2A > G (p.?) [29]
(p.Asp139Hisfs*2) c.415_416del (p.Asp139Hisfs*2)
rg172*) c.622A > T (p.Arg208*) [30, 31]
(p.Gly195Ilefs*13) c.579_580del (p.Gly195Ilefs*13) [32]
.Arg440Gln) c.1319G > A (p.Arg440Gln) [31–34]
A (p.?) c.1046 T > C (p.Leu349Ser) [32, 33, 35]
237Leufs*10) No mutation detected
Watson et al. BMC Medical Genetics  (2016) 17:1 Page 5 of 9extent of the deleted sequence was defined by the pro-
ximity of captured flanking exons; this refined the maximal
extent of each deletion to 9.9 kb and 25.5 kb, respectively.
Retrospective inspection of aligned sequence reads
within the putative disease-containing loci did not reveal
any homozygous non-reference (or heterozygous) vari-
ants to support (or oppose) the existence of the deleted
sequences. Inspecting the alignment BAM files in the In-
tegrated Genome Viewer did however reveal a halving of
relative read depth at both deletion-containing loci. To
validate our findings and delineate the intragenic break-
points, we performed medium-coverage (9×) WGS using
a longer, 175-bp sequencing read. To reduce adaptor
read-through, the library insert, size was increased from
~200 bp to ~250 bp. Despite this, ~20 % adaptor-trimmed
reads were present in the sequenced dataset (Table 2). Un-
mapped reads were recovered from the alignment BAM
file and a split-read mapping algorithm was used to search
for reads spanning the deletion breakpoint. For the AHI
variant, a single such read was identified, indicating a dele-
tion of 5,330 nucleotides, while for the TMEM237/MPP4
variant two reads were identified, suggesting a deletion of
24,074 nucleotides. The number of aligned nucleotides on
either side of the breakpoint and their genomic coordi-
nates, identified using BLAT, are listed in Table 3. The
positions and orientations of these breakpoint-spanning
reads with respect to the human reference sequence and
UCSC RepeatMasker track are shown in Fig. 1. The
centromeric end of the AHI1 variant intersects a MER20
DNA repeat and the TMEM237/MPP4 variant intersects
two low complexity Alu repeat elements.
Sanger sequencing of breakpoint-spanning PCR prod-
ucts confirmed the identity of both amplicons and that
the breakpoints were clean deletions with no inserted
nucleotides (Fig. 2a and b). To genotype the multi-exon
AHI1 deletion variant in the extended family a multiplex
PCR was used which incorporated both the normal- and
deletion-specific forward primers in conjunction with a
common reverse primer (Fig. 2c). In heterozygous muta-
tion carriers, a larger mutation-specific PCR product is
visible in addition to the normal band. The assay con-
firmed that the proband inherited the deletion-containing
allele from her father and that her affected brother was
also heterozygous for the mutation. In conjunction with
the segregation of the pathogenic AHI1 single-base dele-
tion, c.1983del (p.Trp662Glyfs*24), this confirmed that theTable 2 Summary metrics for medium coverage whole genome seq
Sample number Read type Raw read count Trimmed reads (%)
1 175-bp SR 166055253 18.1
16 175-bp SR 141082846 21.0
SR single read
aFollowing duplicate removaltwo variants were present in trans in both affected
siblings.
Discussion
NGS workflows suitable for detecting single nucleotide
and small insertion/deletion variants are now well estab-
lished throughout the genetic diagnostic community.
Many assays initially used long-range PCR as the target
enrichment method [19], but owing to the finite number
of long-range PCR primers that can be sustainably han-
dled, enrichment is now more typically performed using
hybridisation capture. Furthermore, the robustness and
quality assurance provided by a pre-designed “off-the-
shelf” reagent, as well as the potential to target much
larger genomic regions, has added to the increased
popularity of this methodology. For staff undertaking
NGS library production, a single laboratory method
streamlines the workflow and increases productivity. For
analysis, establishing a new diagnostic test can be as
straightforward as adjusting the genomic coordinates of
the targeted regions. These factors are enabling diagnos-
tic laboratories to maintain pace with the emergence of
newly reported gene associations. In our centre, we now
routinely undertake targeted diagnostic exome analysis
of JBTS- and MKS-associated genes. We were able to
confirm diagnoses in 14 of the first 26 cases, a diagnostic
yield of 54 %. This may increase in light of new evidence,
as it is possible that variants deemed to be of uncertain
clinical significance, may be re-classified as pathogenic,
disease-causing, mutations. Alternatively, the “missing”
disease-causing mutations may be located in genomic
regions that were not targeted either for sequencing (e.g.
promoters or introns) or analysis (genes yet to be recog-
nised as disease-associated). For example, common bio-
logical mechanisms involving ciliary structure and
function may imply genetic relatedness between JBTS/
MKS and the wider spectrum of “ciliopathies”, in which
developmental effects of defective ciliary function are
manifested. Our strategy of analysing a full exome,
rather than a gene set targeting only OMIM genes (a
“clinical exome”) will allow us to re-analyse quickly, as
new disease-associated genes continue to be reported. It
is likely that this will be driven by multi-centre consortia
capable of amassing many hundreds of similarly affected
patients as has been recently reported by Bachmann-
Gagescu et al. [20]. The diagnostic yield in their studyuencing data
Reads identified as duplicates (%) Mapped readsa Unmapped reads
4.20 141464444 18391865
4.32 117693041 18076624
Table 3 Characteristics of SplazerS-mapped breakpoint spanning reads
Sample
number






Strand Chr 5’ match start 5’ match stop 3’ match start 3’ match stop
1 1:1207:14146:94852 64 111 175 + 6 135750881 135750944 135756275 135756385
16 2:2114:3289:41334 112 58 170 - 2 202529915 202530026 202505783 202505840
16 2:2115:10757:93844 76 99 175 - 2 202529915 202529990 202505742 202505840
Genomic coordinates are provided for hg19 with respect to the strand from which the read was sequenced
nt nucleotides, Chr chromosome
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of identified pathogenic mutations was more diverse,
comprising mutations in 23 of the 27 genes they analysed.
The considerable number of cases of South Asian ethni-
city (13 patients), for whom consanguineous marriage is
customary, may account for the relative homogeneity of
pathogenic mutations identified in our cohort. That the
TCTN2 mutation c.1506-2A >G was identified in four
individuals, all of whom were South Asian, suggests this
variant may be a founder mutation in this population.
Seventeen cases (65 %) were referred for testing with a
clinical diagnosis of MKS, so it is unsurprising that an
MKS locus accounts for the greatest number of different
pathogenic variants in our cohort. Given the accelerating
rate of new gene discovery, the ability to reanalyse existing
datasets is likely to be of particular clinical utility [21].
Comparative read-depth analysis enabled the identifi-
cation of two heterozygous deletion variants in trans
with pathogenic point mutations. It is worth noting that
the use of whole exome sequencing allowed us to better
define the maximal extent of the intergenic TMEM237/
MPP4 deletion than would have been possible had we
used a reagent targeting only known JBTS/MKS genes.
(If limited sequencing capacity precludes the use ofFig. 1 A schematic representation of SplazerS-identified breakpoint-spannin
TMEM237 to MPP4 deletion. Red and blue arrowed boxes denote reads ma
names of RepeatMasker-identified sequence elements. Genomic coordinateroutine exome sequencing, one alternative approach
might be to add capture probes for the exons of genes
flanking the targeted genes.) Although multiplex-ligation
probe (MLPA) assays are widely regarded as the “gold-
standard” technique for detecting exonic deletions and
duplications, the production of validated reagents cannot
keep pace with ever expanding targeted gene panels. In
contrast, our CNV analyses did not require additional la-
boratory reagents or staff costs.
While it is conceptually and practically straightforward
to identify homozygous deletions, due to the absence of
sequence reads at normally well-captured genomic loci,
automated identification of heterozygous deletions and
duplications is more challenging and the sensitivity of
CNV detection remains poorly defined. Limitations
probably include reduced sensitivity of detection of CNVs
encompassing GC-rich regions. Such regions, which often
include a gene’s first exon, are consistently reported to be
poorly captured using hybridisation enrichment technolo-
gies [22]. Consequently, custom capture reagent designs,
targeting fewer loci than an exome, may overcome prob-
lems associated with regions of repeatedly poor sequence
coverage by allowing an increase in capture probe
density in specific underrepresented regions. An importantg reads for (a) the intragenic AHI1 deletion and (b) the intergenic
pping to the (+) and (−) strands respectively. Black tracks contain the
s are for build hg19. Chromosome
Fig. 2 Sanger sequencing chromatograms verifying the deletion breakpoints for (a) the intragenic AHI1 deletion and (b) the deletion spanning
TMEM237 to MPP4. c A diagnostic multiplex PCR assay showing amplification products for normal (356-bp) and deletion-containing (582-bp) AHI1
alleles. Both affected siblings are heterozygous for the deletion-containing allele, which was inherited from their father
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analyses is the origin of the control dataset, specifically
whether it is derived from inter-batch or intra-batch
samples. In targeted exome analyses, available sequencer
capacity probably limits the ability of most diagnostic
laboratories to pool enough samples in one experiment
for robust intra-batch normalisation. This approach may
therefore be more amenable to the analysis of smaller tar-
geted panels, in which more NGS libraries can be pooled.
Regardless of the method used to define the control co-
hort, knowledge of a disorder’s mutation spectrum is of
paramount importance. Including in a reference control
pool cases for which there is a high prior probability of a
CNV (or including family members) could dilute the
effect of a true deviation in relative read-depth.
The ability to detect CNVs in hybridisation enrich-
ment experiments is influenced by gene size and struc-
ture. A deletion of large genomic extent could be missed
if exons are sparsely distributed, reducing the number of
available data-points. Similar considerations apply when
trying to define the boundaries of a putative CNV. Con-
sequently, for genes within which CNVs account for asignificant component of the mutation spectrum, it may
prove beneficial to include additional capture probes
within surrounding introns. Although our investigations
have revealed two cases in whom dosage variants account
for the pathogenic disease allele, we have identified too
few events to ascribe a precise sensitivity and specificity to
this workflow. Future efforts in this area are likely to be
hindered, in the short-term, by the paucity of identified
pathogenic copy-number alleles. As such, without per-
forming whole genome sequencing of the entire cohort, it
will not be possible to completely exclude pathogenic dos-
age mutations in JBTS or MKS disease associated genes in
the reported patients.
We confirmed candidate CNVs using medium cover-
age (9×) WGS, an increasingly cost-effective solution
which enabled nucleotide-resolution breakpoint detec-
tion to be delivered in a regional diagnostic laboratory.
We used an unsupported 175-bp sequencing protocol,
but the recent release of 2 × 250-bp kits should further
improve the power of this approach to CNV validation.
The length of read available for alignment is especially
important when performing split-read alignments, as the
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read. The sequence context surrounding the breakpoint
will also have a direct bearing on its ability to be detected.
Both breakpoints reported here were located within ele-
ments identified by RepeatMasker. Low complexity se-
quences are difficult to align to a reference sequence using
short read technology. Although we were able to imple-
ment customised sequencer run configurations, these will
not be available to all diagnostic laboratories. For these
centres, the identification of discordant read pairs (for
which the read mapping positions are at variance with the
expected library insert size) may offer an alternative route
to validating CNVs.
Defining CNVs at single-nucleotide resolution permits
inexpensive PCR-based genotyping assays to be deployed
for testing the extended family, as demonstrated above
for case 1.
Conclusions
The CNVs identified here have not previously been re-
ported in the literature and therefore expand the JBTS
mutation spectrum. With ever-improving mutation de-
tection techniques, it is likely that dosage variants will
be more frequently identified and characterised at nu-
cleotide resolution. The CNVs we describe are smaller
than those typically detected by diagnostic array-CGH
or by our standard genome-wide copy number sequen-
cing (CNVseq) approach [23]. Although the sensitivity
gap between front-line aCGH/CNVseq technologies and
the limits of detection using the comparative read-depth
approach are ill-defined, they will probably be bridged as
the cost of WGS falls in future years. In the interim, our
present report, emphasizes the additional diagnostic
yield that can be obtained at little cost, using modifica-
tions of current analytical approaches.
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